Genmab A/S
DKFinancials
Valuation Metrics
Genmab A/S's Market Cap is $33.72B. At end of 2025 it was $18.98B. Ranked #411 of 3,118 in US market (top 13%), #120 of 1,474 on NASDAQ (top 8%), #25 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $33.72B | US#411/3,118 Sec#25/265 |
| Net Income | $788M | US#641/3,118 Sec#23/265 |
| Total Assets | $12.52B | US#858/3,118 Sec#27/265 |
| Net Assets | $5.96B | US#619/3,118 Sec#28/265 |
| Employees | 3,119 | US#1,452/3,118 Sec#33/265 |
| Value | ||
| P/E | 42.78x | US#1,857/3,118 Sec#50/265 |
| P/B | 5.66x | US#2,342/3,118 Sec#157/265 |
| P/S | 9.06x | US#2,682/3,118 Sec#115/265 |
| EV/EBITDA | 30.74x | US#2,237/3,118 Sec#62/265 |
| FCF Yield | 2.57% | US#1,935/3,118 Sec#63/265 |
| Profitability | ||
| ROE | 13.23% | US#1,023/3,118 Sec#42/265 |
| ROA | 6.30% | US#873/3,118 Sec#48/265 |
| Financial Health | ||
| Debt Ratio | 110.09% | US#1,183/3,118 Sec#170/265 |
| Total Debt | $5.27B | US#647/3,118 Sec#24/265 |
| FCF | $867M | US#641/3,118 Sec#29/265 |
| Cash | $1.50B | US#530/3,118 Sec#24/265 |
| Current Ratio | 2.46x | US#987/3,118 Sec#202/265 |
| Net Debt/EBITDA | 3.09x | US#1,652/3,118 Sec#64/265 |
| Performance | ||
| 1Y Return | 91.96% | US#150/3,118 Sec#38/265 |
| 1M Return | 58.04% | US#10/3,118 Sec#2/265 |
| From 52W High | -8.42% | US#407/3,118 Sec#31/265 |
| 1Y MDD | -32.51% | US#1,474/3,118 Sec#75/265 |
| Trading | ||
| Volume | 3,941,458 shares | US#233/3,118 Sec#14/265 |
| Trading Value | $219M | US#238/3,118 Sec#15/265 |
| Per Share | ||
| EPS | $1.28 | US#1,585/3,118 Sec#47/265 |
| BPS | $9.70 | US#1,860/3,118 Sec#69/265 |
Company Info
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.